Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, is investing an additional $100 million to expand its industrial operations and product supply (IOPS) bioprocessing site in Limerick, Ireland to bring its total investment to the site to $750 million.

Regeneron first announced the investment in 2013. The company has a 400,000-square-foot biologics production facility in Limerick. The additional $100 million investment will support the construction of a number of manufacturing suites to increase drug-substance production capacity.

In addition to the production facility in Limerick, Regeneron’s European Business Operations for IOPS, the company has a growing Dublin office, currently employing 30 people and serving as the company’s European Business Administration headquarters.

Regeneron’s total headcount in Ireland is expected to approach 850 by the end of 2018, according to the company.

Source: Regeneron Pharmaceuticals